{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:35:58Z","timestamp":1740173758186,"version":"3.37.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH Intramural Project","award":["1ZIABC011768-03"],"award-info":[{"award-number":["1ZIABC011768-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study explored differences in patient-reported outcomes (PROs) for patients with central nervous system (CNS) tumors during COVID, compared to pre-pandemic assessments, in light of impacted access to in-person care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patient-reported outcomes (PROMIS-Anxiety and Depression Short-Forms, EQ-5D-3L, MDASI-BT\/Spine, NeuroQoL-Perceived Cognitive Functioning) were collected from 149 participants on the Neuro-Oncology Branch Natural History Study seen during the first year of COVID between March 2020 and February 2021, which were compared to assessments collected pre-COVID. Paired sample t-tests and proportion tests (z-tests) were used to compare PROs with effect sizes reported using Hedges g and Cohen\u2019s h. Logistic regression models with backwards selection were used to identify risk factors for high levels of depression and anxiety pre- and during COVID.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Participants were primarily male (54%) and Caucasian (84%) with a median age of 46 (range 20\u201379) and 66% had high-grade tumors. More patients reported moderate-severe depressive symptoms during the COVID year, compared to pre-COVID assessments (13% vs 8%, Cohen\u2019s h\u2005=\u20050.17, P\u2005=\u2005.021), with modest increases in symptom burden and cognitive dysfunction reported as well. Logistic regressions revealed that during COVID, concurrent moderate-severe distress and low tumor grade predicted depression and anxiety, with psychotropic medication use also predicting depression while active treatment predicted anxiety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>During COVID, patients experienced higher levels of depression, which has the potential to negatively influence treatment success and survival. Future work is needed to incorporate innovative tools and interventions that can be utilized remotely to identify and target mood disturbance in these vulnerable patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npae067","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T13:59:35Z","timestamp":1721224775000},"page":"76-86","source":"Crossref","is-referenced-by-count":0,"title":["The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-6914","authenticated-orcid":false,"given":"Amanda L","family":"King","sequence":"first","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla N","family":"Roche","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Vera","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Pillai","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. , Frederick, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Polskin","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. , Frederick, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvina A","family":"Acquaye-Mallory","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Boris","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. , Frederick, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Burton","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Choi","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. , Frederick, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Grajkowska","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather E","family":"Leeper","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Panzer","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. , Frederick, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Penas-Prado","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Reyes","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solmaz","family":"Sahebjam","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett J","family":"Theeler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-9646","authenticated-orcid":false,"given":"Jing","family":"Wu","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri S","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"issue":"4","key":"2025020601104436800_CIT0001","first-page":"460","article-title":"Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study","volume":"8","author":"Rogers","year":"2021","journal-title":"Neurooncol Pract."},{"issue":"2","key":"2025020601104436800_CIT0002","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/neuonc\/nov166","article-title":"The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms","volume":"18","author":"Armstrong","year":"2016","journal-title":"Neuro Oncol."},{"issue":"3","key":"2025020601104436800_CIT0003","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cncr.30355","article-title":"Clinical presentation and outcomes for adult ependymoma patients","volume":"123","author":"Acquaye","year":"2017","journal-title":"Cancer."},{"issue":"4","key":"2025020601104436800_CIT0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/cns-2016-0010","article-title":"Psychosocial distress and its effects on the health-related quality of life for primary brain tumor patients","volume":"5","author":"Randazzo","year":"2018","journal-title":"CNS Oncol."},{"issue":"1","key":"2025020601104436800_CIT0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1099-1611(200101\/02)10:1<19::AID-PON501>3.0.CO;2-6","article-title":"The prevalence of psychological distress by cancer site","volume":"10","author":"Zabora","year":"2001","journal-title":"Psychooncology."},{"issue":"6","key":"2025020601104436800_CIT0006","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1634\/theoncologist.2009-0291","article-title":"Review on quality of life issues in patients with primary brain tumors","volume":"15","author":"Taphoorn","year":"2010","journal-title":"Oncologist."},{"issue":"2","key":"2025020601104436800_CIT0007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cmrp.2020.03.011","article-title":"Effects of COVID-19 pandemic in daily life","volume":"10","author":"Haleem","year":"2020","journal-title":"Curr Med Res Pract."},{"issue":"9","key":"2025020601104436800_CIT0008","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/pon.5434","article-title":"Quality of life of cancer patients during coronavirus disease (COVID-19) pandemic","volume":"29","author":"Ciazynska","year":"2020","journal-title":"Psychooncology."},{"issue":"1","key":"2025020601104436800_CIT0009","first-page":"vdaa104","article-title":"Brain tumors and COVID-19: the patient and caregiver experience","volume":"2","author":"Voisin","year":"2020","journal-title":"Neurooncol Adv."},{"issue":"4","key":"2025020601104436800_CIT0010","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s00520-021-06789-3","article-title":"Anxiety and depression in patients with advanced cancer during the COVID-19 pandemic","volume":"30","author":"Obispo-Portero","year":"2022","journal-title":"Support Care Cancer."},{"issue":"2","key":"2025020601104436800_CIT0011","doi-asserted-by":"crossref","first-page":"E628","DOI":"10.1097\/NCC.0000000000000937","article-title":"Do COVID-19-related treatment changes influence fear of cancer recurrence, anxiety, and depression in breast cancer patients","volume":"45","author":"Kim","year":"2022","journal-title":"Cancer Nurs."},{"issue":"1","key":"2025020601104436800_CIT0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11060-006-9135-z","article-title":"Validation of the M.D. Anderson Symptom Inventory Brain Tumor module (MDASI-BT)","volume":"80","author":"Armstrong","year":"2006","journal-title":"J Neurooncol."},{"issue":"4","key":"2025020601104436800_CIT0013","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3171\/2009.10.SPINE0943","article-title":"Reliability and validity of the MD Anderson Symptom Inventory\u2013Spine Tumor module","volume":"12","author":"Armstrong","year":"2010","journal-title":"J Neurosurg Spine"},{"key":"2025020601104436800_CIT0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jclinepi.2015.08.036","article-title":"Clinical validity of PROMIS\u00ae Depression, Anxiety, and Anger across diverse clinical samples","volume":"73","author":"Schalet","year":"2016","journal-title":"J Clin Epidemiol."},{"article-title":"User manual for the quality","year":"2017","author":"NINDS","key":"2025020601104436800_CIT0015"},{"issue":"23","key":"2025020601104436800_CIT0016","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","article-title":"Neuro-QoL: brief measures of health-related quality of life for clinical research in neurology","volume":"78","author":"Cella","year":"2012","journal-title":"Neurology."},{"issue":"2","key":"2025020601104436800_CIT0017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40271-020-00466-z","article-title":"Measurement properties of the EQ-5D-5L and EQ-5D-3L in six commonly diagnosed cancers","volume":"14","author":"Zeng","year":"2021","journal-title":"Patient"},{"issue":"3","key":"2025020601104436800_CIT0018","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQoL: a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQoL Group","year":"1990","journal-title":"Health Policy"},{"issue":"3","key":"2025020601104436800_CIT0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care."},{"volume-title":"IBM SPSS Statistics for","year":"2021","author":"IBM Corp","key":"2025020601104436800_CIT0020"},{"issue":"1","key":"2025020601104436800_CIT0021","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/curroncol28010034","article-title":"COVID-19 pandemic stressors and psychological symptoms in breast cancer patients","volume":"28","author":"Massicotte","year":"2021","journal-title":"Curr Oncol."},{"issue":"3","key":"2025020601104436800_CIT0022","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4143\/crt.2021.585","article-title":"Functional impairments in the mental health, depression, and anxiety related to the viral epidemic and disruption in the healthcare service utilization among cancer patients in the COVID-19 pandemic era","volume":"54","author":"Kim","year":"2021","journal-title":"Cancer Res Treat."},{"issue":"1","key":"2025020601104436800_CIT0023","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12992-020-00589-w","article-title":"Prevalence of stress, anxiety, and depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis","volume":"16","author":"Salari","year":"2020","journal-title":"Global Health."},{"issue":"1","key":"2025020601104436800_CIT0024","first-page":"20","article-title":"Cognitive therapy for adjustment disorder in cancer patients","volume":"1","author":"Schuyler","year":"2004","journal-title":"Psychiatry."},{"issue":"2","key":"2025020601104436800_CIT0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1215\/15228517-2007-057","article-title":"Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors","volume":"10","author":"Arnold","year":"2008","journal-title":"Neuro Oncol."},{"issue":"283","key":"2025020601104436800_CIT0026","article-title":"Mental adjustment to cancer and its relation to anxiety, depression, HRQL and survival in patients with laryngeal cancer: a longitudinal study","volume":"11","author":"Johansson","year":"2011","journal-title":"BMC Cancer."},{"issue":"8","key":"2025020601104436800_CIT0027","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/cncr.22980","article-title":"Psychiatric disorders in advanced cancer","volume":"110","author":"Myovic","year":"2007","journal-title":"Cancer."},{"issue":"1","key":"2025020601104436800_CIT0028","doi-asserted-by":"crossref","first-page":"pkaa104","DOI":"10.1093\/jncics\/pkaa104","article-title":"Impact of the COVID-19 pandemic on patient-reported outcomes of breast cancer patients and survivors","volume":"5","author":"Bargon","year":"2021","journal-title":"JNCI Cancer Spectr."},{"key":"2025020601104436800_CIT0029","article-title":"Impact of depression","volume-title":"Depression and Cancer","author":"DiMatteo","year":"2011"},{"issue":"14","key":"2025020601104436800_CIT0030","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1002\/cncr.25892","article-title":"The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor module (MDASI-BT) on prediction of recurrence in primary brain tumor patients","volume":"117","author":"Armstrong","year":"2011","journal-title":"Cancer."},{"key":"2025020601104436800_CIT0031","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cobeha.2019.01.009","article-title":"The interplay among psychological distress, the immune system, and brain tumor patient outcomes","volume":"28","author":"Otto-Meyer","year":"2019","journal-title":"Curr Opin Behav Sci."},{"key":"2025020601104436800_CIT0032","first-page":"341","article-title":"Biobehavioral influences","volume-title":"Psychoneuroimmunology and Cancer","author":"Lutgendorf","year":"2012"},{"key":"2025020601104436800_CIT0033","article-title":"Pancreatic cancer progression and mortality predicted by depression and anxiety: a systematic review and meta-analysis protocol","volume":"14","author":"Zhang","year":"2023","journal-title":"Psychiatry."},{"key":"2025020601104436800_CIT0034","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.wneu.2020.05.066","article-title":"Telemedicine in the era of coronavirus disease 2019 (COVID-19): a neurosurgical perspective","volume":"139","author":"Blue","year":"2019","journal-title":"World Neurosurg."},{"issue":"8","key":"2025020601104436800_CIT0035","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jnci\/djaa200","article-title":"Readdressing the needs of cancer survivors during COVID-19: a path forward","volume":"113","author":"Jones","year":"2021","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"2025020601104436800_CIT0036","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring versus routine surveillance following treatment for lung cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA."},{"key":"2025020601104436800_CIT0037","first-page":"947","article-title":"Clinical utility and user perceptions of a digital system for electronic patient-reported symptom monitoring during routine cancer care: findings from the PRO-TECT trial","volume":"4","author":"Basch","year":"2020","journal-title":"J Clin Oncol."},{"issue":"23","key":"2025020601104436800_CIT0038","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1200\/JCO.2017.77.1097","article-title":"Managing Cancer and Living Meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer","volume":"36","author":"Rodin","year":"2018","journal-title":"J Clin Oncol."},{"issue":"262","key":"2025020601104436800_CIT0039","article-title":"Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: study protocol for a phase 2 clinical trial","volume":"23","author":"King","year":"2023","journal-title":"BMC Cancer."},{"issue":"1","key":"2025020601104436800_CIT0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-023-04271-0","article-title":"Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: interim analysis of a phase 2 clinical trial","volume":"162","author":"King","year":"2023","journal-title":"J Neurooncol."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npae067\/58894147\/npae067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/1\/76\/58894147\/npae067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/1\/76\/58894147\/npae067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T01:11:03Z","timestamp":1738804263000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/12\/1\/76\/7717121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npae067","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"type":"print","value":"2054-2577"},{"type":"electronic","value":"2054-2585"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,7,19]]}}}